ACR & Coalition Letters to Federal Policymakers

Rheumatology advocacy involves several branches of government and various agencies. ACR advocates to Congress, federal agencies, and others by writing or signing on to various policy letters.

2020 Federal Advocacy Letters

ACR Signs Coalition Letter to CMS Supporting E/M Valuation and Complexity Code Policies - 2/10/2020

2019 Federal Advocacy Letters

ACR Comments to CMS on CY2020 Physician Fee Schedule and Quality Payment Program Final Rule - 12/31/19

Coalition Letter to Congress Supporting CMS E/M Updates - 11/21/19

Coalition Letter to House on Surprise Billing - 10/16/19

Coalition Letter to Senate on Surprise Billing - 10/16/19

Coalition Letter to Congress Supporting Pediatric Specialty Workforce, S.2443 - 10/24/19

ACR Comments on Physician Fee Schedule and Quality Payment Program 2020 Proposed Rule - 9/16/19

Coalition Letter to Congress Urging Prior Authorization Reform, H.R. 3107 - 9/9/19

ACR Comments on Electronic Prior Authorization Part D Proposed Rule - 8/16/19

ACR Comments on Senate Finance Drug Pricing Proposals - 7/24/19

ACR Support for H.R. 2373 Prescription Pricing for the People Act - 7/9/19

ACR Feedback on Draft Medicare Part D Legislation - 6/6/19

Coalition Letter on Needed MACRA improvements - 6/3/19

ACR Comments to FDA on Nonproprietary Naming of Biological Products - 5/7/19

ACR Comments on Safe Harbor Rebate Rule - 4/8/19

Coalition Letter on Step Therapy - 4/8/19

ACR Comments on Pain Management Best Practices - 4/1/19

ACR Comments on Notice of Benefit and Payment Parameters for 2020 Proposed Rule - 2/19/19

ACR Comments on Part D Medicare Advantage Proposed Rule - 1/22/19

ACR Comments on Healthy People 2030 Objectives - 1/17/19

2018 Federal Advocacy Letters

ACR Comments on 2019 Medicare Physician Fee Schedule Final Rule - 12/31/18

ACR Comments on Medicare Part B Drugs International Pricing Index Model - 12/27/18

Coalition Letter on Medicare Advantage Step Therapy - 10/1/18

ACR Response to CMS on Competitive Acquisition Program Request for Information - 9/24/18

ACR Letter to CMS on 2019 Physician Fee Schedule and Quality Payment Program - 9/6/18

ACR Comments in FDA Public Meeting on Biosimilars - 9/5/18

Stakeholder Letter to CMS on E/M Proposals in 2019 Medicare Physician Fee Schedule - 8/28/18

ACR Letter to HHS on Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs - 7/13/18

Coalition Letter to CMS on Shortening the 2018 MIPS Reporting Period - 4/27/18

ACR Letter to CMS on Short-Term Limited Duration Insurance - 4/23/18

Coalition Letter to CMS on Short-Term Limited Duration Insurance - 4/23/18

Coalition Letter to CMS on Prior Authorization under Medicare Advantage and the Patients Over Paperwork Initiative - 4/4/18

Physician Group Letter to HHS on Drug Pricing Proposals - 3/14/18

ACR Comments to CMS on Clinical Laboratory Improvement Amendments - 3/12/18

ACR Comments to Department of Labor on Association Health Plan Proposed Rule - 3/5/18

ACR Response to HHS Request for Information on Promoting Healthcare Choice and Competition - 1/25/18

ACR Letter to FDA: Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases - 1/19/18

Coalition Letter to House on MIPS Adjustment to Part B Drugs - 1/18/18

Coalition Letter to Senate on MIPS Adjustment to Part B Drugs - 1/18/18

ACR Letter to CMS on Medicare Advantage Proposed Rule - 1/16/18